Neumora Therapeutics Inc (NMRA) Sheds More Light on Phase 1b Study of NMRA-511 [Yahoo! Finance]
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at William Blair from a "market perform" rating to an "outperform" rating.
Neumora Therapeutics to Participate in Guggenheim Emerging Outlook: Biotech Summit 2026
Neumora Therapeutics (NASDAQ:NMRA) was upgraded by analysts at Leerink Partnrs to a "strong-buy" rating.
Neumora Therapeutics (NASDAQ:NMRA) is now covered by analysts at Leerink Partners. They set an "outperform" rating and a $8.00 price target on the stock.